ATE427354T1 - Mage-a3 polypeptide die durch hla-klasse ii molekule prasentiert werden - Google Patents

Mage-a3 polypeptide die durch hla-klasse ii molekule prasentiert werden

Info

Publication number: ATE427354T1
Authority: AT; Austria
Prior art keywords: mage; hla class; molecules; polypeptides presented; peptides
Prior art date: 1998-10-05

Application number

AT99970121T

Other languages

English (en)

Inventor

Pascal Chaux

Vincent Stroobant

Thierry Boon-Falleur

Der Bruggen Pierre Van

Erwin Schultz

Snick Jacques Van

Bernard Lethe

Kris Thielemans

Jurgen Corthals

Carlo Heirman

Original Assignee

Ludwig Inst For Cancer Res Ltd

Univ Bruxelles

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-05

Filing date

1999-09-15

Publication date

2009-04-15

1999-09-15 Application filed by Ludwig Inst For Cancer Res Ltd, Univ Bruxelles filed Critical Ludwig Inst For Cancer Res Ltd

2009-04-15 Application granted granted Critical

2009-04-15 Publication of ATE427354T1 publication Critical patent/ATE427354T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 title 1
229920001184 polypeptide Polymers 0.000 title 1
108090000623 proteins and genes Proteins 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/13—B-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT99970121T 1998-10-05 1999-09-15 Mage-a3 polypeptide die durch hla-klasse ii molekule prasentiert werden ATE427354T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/166,448 US6291430B1 (en)	1997-09-12	1998-10-05	Mage-3 peptides presented by HLA class II molecules

Publications (1)

Publication Number	Publication Date
ATE427354T1 true ATE427354T1 (de)	2009-04-15

Family

ID=22603350

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99970121T ATE427354T1 (de)	1998-10-05	1999-09-15	Mage-a3 polypeptide die durch hla-klasse ii molekule prasentiert werden

Country Status (7)

Country	Link
US (3)	US6291430B1 (de)
EP (1)	EP1119623B1 (de)
JP (1)	JP4102027B2 (de)
AT (1)	ATE427354T1 (de)
AU (1)	AU772720B2 (de)
DE (1)	DE69940671D1 (de)
WO (1)	WO2000020581A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2224113T5 (es) *	1994-02-16	2009-05-01	The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services	Polipeptido antigenico asociado al melanoma, epitopos del mismo y vacunas contra melanoma.
US20040156861A1 (en) *	1996-07-11	2004-08-12	Figdor Carl Gustav	Melanoma associated peptide analogues and vaccines against melanoma
US7888100B2 (en) *	1996-10-03	2011-02-15	Memorial Sloan-Kettering Cancer Research	Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
BR9907691B1 (pt) *	1998-02-05	2011-05-31		derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
US20030138808A1 (en) *	1998-02-19	2003-07-24	Simard John J.L.	Expression vectors encoding epitopes of target-associated antigens
IT1312568B1 (it) *	1999-05-21	2002-04-22	Genera Spa	Peptidi immunogenici e loro uso.
US7429639B2 (en)	1999-09-29	2008-09-30	Ludwig Institute For Cancer Research	SSX-2 peptides presented by HLA class II molecules
US20030215425A1 (en) *	2001-12-07	2003-11-20	Simard John J. L.	Epitope synchronization in antigen presenting cells
US7851212B2 (en) *	2000-05-10	2010-12-14	Sanofi Pasteur Limited	Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
US7049413B2 (en) *	2001-05-18	2006-05-23	Ludwig Institute For Cancer Research	MAGE-A3 peptides presented by HLA class II molecules
US20030113919A1 (en) *	2001-08-17	2003-06-19	Aventis Pasteur, Ltd.	Immunogenic targets for melanoma
US20030232013A1 (en) *	2002-02-22	2003-12-18	Gary Sieckman	Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
DE10213493A1 (de) *	2002-03-26	2003-10-16	Stephan Grabbe	Verfahren zur Aktivierung von dendritischen Zellen
FR2837837B1 (fr)	2002-03-28	2006-09-29	Roussy Inst Gustave	Epitopes peptidiques communs a des antigenes d'une meme famille multigenique
US20030206916A1 (en) *	2002-05-03	2003-11-06	Rush-Presbyterian-St. Luke's Medical Center	Immunogenic peptides
US7041502B2 (en) *	2002-06-05	2006-05-09	Ludwig Institute For Cancer Research	Isolated peptides which bind to HLA-B18 molecules and uses thereof
WO2005007673A2 (en) *	2003-07-03	2005-01-27	Rush University Medical Center	Immunogenic peptides
ATE496129T1 (de)	2003-07-22	2011-02-15	Ludwig Inst Cancer Res	Von hla-klasse-ii-molekülen präsentierte ssx-2- peptide
GB0323968D0 (en) *	2003-10-13	2003-11-19	Glaxosmithkline Biolog Sa	Immunogenic compositions
CA2542686A1 (en) *	2003-10-15	2005-05-06	Istituto Superiore Di Sanita	Colorectal cancer antigen
US20070154889A1 (en) *	2004-06-25	2007-07-05	Veridex, Llc	Methods and reagents for the detection of melanoma
WO2006045750A2 (en) *	2004-10-20	2006-05-04	Friedrich-Alexander- Universität Erlangen- Nürnberg	T-cell stimulatory peptides from the melanoma-associated chondroitin sulfate proteoglycan and their use
CA2523032A1 (en)	2005-10-07	2007-04-07	Immunovaccine Technologies Inc.	Vaccines for cancer therapy
WO2008053573A1 (fr)	2006-10-30	2008-05-08	National University Corporation Hokkaido University	Remède pour néoplasme malin
NZ596545A (en)	2007-09-17	2013-05-31	Glaxosmithkline Biolog Sa	Improved detection of mage-a expression
ES2588705T3 (es) *	2007-09-27	2016-11-04	Immunovaccine Technologies Inc.	Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20100209452A1 (en) *	2007-10-03	2010-08-19	Immunovaccine Technologies, Inc	Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
CA2723918C (en)	2008-06-05	2018-01-09	Immunovaccine Technologies Inc.	Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
WO2012088414A1 (en)	2010-12-23	2012-06-28	Ludwig Institute For Cancer Research Ltd.	Liposomal formulation of nonglycosidic ceramides and uses thereof
IN2014CN02581A (de)	2011-10-06	2015-08-07	Immunovaccine Technologies Inc
EP2785683B1 (de)	2011-11-30	2020-02-05	Ludwig Institute for Cancer Research Ltd.	Inkt-zellmodulatoren und verwendungsverfahren dafür
WO2013134365A1 (en)	2012-03-08	2013-09-12	Ludwig Institute For Cancer Research Ltd	TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
WO2013134665A1 (en)	2012-03-08	2013-09-12	Selig Sealing Products, Inc.	Container sealing member with protected security component and removal tab
US9895549B2 (en)	2012-11-06	2018-02-20	The Florida International University Board Of Trustees	On-demand drug release using magneto-electric nanoparticles
WO2014074584A1 (en)	2012-11-06	2014-05-15	Sakhrat Khizroev	On-demand drug release using magneto-electric nanoparticles
US9976146B2 (en) *	2014-05-30	2018-05-22	Academia Sinica	Aptamer targeting MAGE-A3 peptide and uses thereof
WO2016094309A1 (en)	2014-12-10	2016-06-16	Myosotis	Inhibition of tnf signaling in cancer immunotherapy
IL301919A (en) *	2015-03-27	2023-06-01	Immatics Biotechnologies Gmbh	Innovative peptides and a combination of peptides for use in immunotherapy against various tumors
GB201505305D0 (en) *	2015-03-27	2015-05-13	Immatics Biotechnologies Gmbh	Novel Peptides and combination of peptides for use in immunotherapy against various tumors
EP3307772B1 (de)	2015-06-12	2020-09-09	Ludwig Institute For Cancer Research Limited	Tgf-beta-3-spezifische antikörper und verfahren sowie verwendungen davon
MX2017016844A (es)	2015-07-16	2018-08-15	Biokine Therapeutics Ltd	Composiciones y procedimientos para tratar cancer.
GB201519340D0 (en)	2015-11-02	2015-12-16	Cambridge Entpr Ltd	Methods of T-lymphocyte expansion
GB201519481D0 (en)	2015-11-04	2015-12-16	Cancer Rec Tech Ltd	Immunomodulatory antibodies
GB201616238D0 (en)	2016-09-23	2016-11-09	Adaptimmune Ltd	Modified T cells
ES2916217T3 (es)	2017-01-05	2022-06-29	Kahr Medical Ltd	Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma
GB201700345D0 (en)	2017-01-09	2017-02-22	F-Star Beta Ltd	Conditional agonists of immune responses
IL250916A0 (en)	2017-03-02	2017-06-29	Geiger Benjamin	Methods for growing t cells in culture and their use
US11945851B2 (en)	2017-06-07	2024-04-02	The Wistar Institute Of Anatomy And Biology	MAGE-A vaccines and methods of treatment using the same
US20210187023A1 (en)	2017-06-27	2021-06-24	The Trustees Of Princeton University	Compositions And Methods For Enhancing Immunotherapy
GB201713078D0 (en)	2017-08-15	2017-09-27	Adaptimmune Ltd	T Cell Modification
CA3081479A1 (en)	2017-11-06	2019-05-09	Ludwig Institute For Cancer Research Ltd	Method for expansion of lymphocytes
CN111836635A (zh)	2018-01-26	2020-10-27	剑桥企业有限公司	肽交换蛋白
CA3104780A1 (en)	2018-07-11	2020-01-16	Kahr Medical Ltd.	Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
GB201811408D0 (en)	2018-07-12	2018-08-29	F Star Beta Ltd	CD137 Binding Molecules
GB201811404D0 (en)	2018-07-12	2018-08-29	F Star Beta Ltd	Anti-CD137 Antibodies
GB201811410D0 (en)	2018-07-12	2018-08-29	F Star Beta Ltd	OX40 Binding molecules
US12606816B2 (en) *	2018-07-31	2026-04-21	Janux Therapeutics, Inc.	Inhibitory T cell receptor peptides and discovery methods
CN122563765A (zh) *	2018-08-10	2026-08-14	北京震旦鼎泰生物科技有限公司	一种用于裸质粒pSFVK1-NMM生产的大肠杆菌发酵培养基
CN109081873B (zh) *	2018-08-10	2022-04-22	固安鼎泰海规生物科技有限公司	一种抗肿瘤重组nmm融合抗原质粒dna疫苗
US12329816B2 (en)	2018-08-24	2025-06-17	The Trustees Of Princeton University	Immunotherapy with metabolic enzyme expression
CA3118027A1 (en)	2018-11-05	2020-05-14	Ludwig Institute For Cancer Research Ltd.	Humanized and variant tgf-.beta.3 specific antibodies and methods and uses thereof
EP3877055A1 (de)	2018-11-05	2021-09-15	Ludwig Institute for Cancer Research Ltd	Humanisierte und variante tgf-beta1-spezifische antikörper sowie verfahren und verwendungen davon
GB201820444D0 (en)	2018-12-14	2019-01-30	Adaptimmune Ltd	Marker for T cell expansion
BR112022000319A2 (pt)	2019-07-11	2022-03-15	Kahr Medical Ltd	Heterodímeros e métodos de uso dos mesmos
GB201911954D0 (en)	2019-08-20	2019-10-02	Adaptimmune Ltd	Lentiviral transduction methods
US20230048719A1 (en)	2019-12-31	2023-02-16	Kahr Medical Ltd.	Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
US20230048361A1 (en)	2019-12-31	2023-02-16	Kahr Medical Ltd.	Methods of culturing t cells and uses of same
IL276599A (en)	2020-08-09	2022-03-01	Yeda Res & Dev	T cell receptor unique to mage-a1 and its uses
US20240317871A1 (en)	2020-12-30	2024-09-26	Immunomic Therapeutics, Inc.	Anti-HVEM Antibodies
US20230132140A1 (en) *	2021-09-15	2023-04-27	Celloram Inc.	Method of treating cancer
US20250262274A1 (en)	2022-05-17	2025-08-21	École Polytechnique Fédérale de Lausanne	Designed Biosensors for Enhanced T Cell Therapy
GB202303250D0 (en)	2023-03-06	2023-04-19	King S College London	Method and compounds
JP2026517843A (ja)	2023-05-03	2026-06-02	アイオーエックスセラピューティクスリミテッド	Ｉｎｋｔ細胞調節剤リポソーム組成物及び使用方法
WO2025155971A1 (en)	2024-01-19	2025-07-24	Immunomic Therapeutics, Inc	Anti-activin receptor 1c (alk-7) receptor antibodies
GB202501534D0 (en)	2025-02-03	2025-03-19	Cambridge Entpr Ltd	Targeted phagocytic degradation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9019409D0 (en)	1990-09-05	1990-10-17	Pfizer Ltd	Therapeutic agents
US6235525B1 (en)	1991-05-23	2001-05-22	Ludwig Institute For Cancer Research	Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en)	1991-05-23	1994-08-30	Ludwig Institute For Cancer Research	Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5405940A (en)	1992-08-31	1995-04-11	Ludwig Institute For Cancer Research	Isolated nonapeptides derived from MAGE genes and uses thereof
SG49008A1 (en)	1993-03-05	1998-05-18	Cytel Corp	Hla-a2.1 binding peptides and their uses
US5851523A (en)	1994-03-24	1998-12-22	Ludwig Institute For Cancer Research.	Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5585461A (en)	1994-03-24	1996-12-17	Ludwig Institute For Cancer Research	Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5686068A (en)	1994-03-24	1997-11-11	Ludwig Institute For Cancer Research	Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
IL126843A (en) *	1996-05-23	2007-06-17	Scripps Research Inst	Mhc class ii antigen-presenting systems and methods for activating cd4+t cells in vitro
US5965535A (en)	1997-09-12	1999-10-12	Ludwig Institute For Cancer Research	Mage-3 peptides presented by HLA class II molecules
CA2323632A1 (en)	1998-03-13	1999-09-16	Epimmune Inc.	Hla-binding peptides and their uses

1998
- 1998-10-05 US US09/166,448 patent/US6291430B1/en not_active Expired - Lifetime
1999
- 1999-09-15 JP JP2000574676A patent/JP4102027B2/ja not_active Expired - Fee Related
- 1999-09-15 EP EP99970121A patent/EP1119623B1/de not_active Expired - Lifetime
- 1999-09-15 DE DE69940671T patent/DE69940671D1/de not_active Expired - Lifetime
- 1999-09-15 AT AT99970121T patent/ATE427354T1/de active
- 1999-09-15 WO PCT/US1999/021230 patent/WO2000020581A1/en not_active Ceased
- 1999-09-15 AU AU60420/99A patent/AU772720B2/en not_active Ceased
2000
- 2000-10-27 US US09/697,884 patent/US6426217B1/en not_active Expired - Lifetime
2002
- 2002-06-12 US US10/170,832 patent/US7252825B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20030170792A1 (en)	2003-09-11
EP1119623A1 (de)	2001-08-01
WO2000020581A1 (en)	2000-04-13
JP2002526110A (ja)	2002-08-20
AU772720B2 (en)	2004-05-06
US7252825B2 (en)	2007-08-07
AU6042099A (en)	2000-04-26
US6291430B1 (en)	2001-09-18
JP4102027B2 (ja)	2008-06-18
US6426217B1 (en)	2002-07-30
DE69940671D1 (de)	2009-05-14
EP1119623B1 (de)	2009-04-01

Legal Events

Date

Code

Title

Description

2009-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1119623

Country of ref document: EP

Publication	Publication Date	Title
DE69940671D1 (de)	2009-05-14	Mage-a3 polypeptide die durch hla-klasse ii molekule präsentiert werden
DE69840868D1 (de)	2009-07-16	Mage-3 peptide, die durch hla-klasse-ii molecule presentiert werden
WO2002095051A3 (en)	2004-02-12	Mage-a3 peptides presented by hla class ii molecules
DK1005540T3 (da)	2004-10-18	IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
WO2001055308A8 (en)	2001-09-07	Nucleic acids, proteins, and antibodies
EP1295944A3 (de)	2004-04-21	GDP-Dissoziation stimulierendes Protein, gehirnspezifisches Nucleosomfügungsprotein, Skelettmuskel-spezifisches Ubiquitin-Conjugationsenzym, Zellproliferationsprotein, Phosphatidylinositolkinase, Nel verwandte Proteine
NZ323795A (en)	2000-01-28	Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
ATE365744T1 (de)	2007-07-15	Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen
WO2001054472A3 (en)	2002-01-31	Nucleic acids, proteins, and antibodies
WO2001055306A3 (en)	2001-12-20	Nucleic acids, proteins, and antibodies
DE69935220D1 (de)	2007-04-05	Von menschlichem tumor stammendes polypeptidhormon phosphatonin
IL207012A0 (en)	2011-08-01	Diagnosis and therapy of cancer using sgp28-related molecules
IL122884A0 (en)	1998-08-16	Enamel matrix related polypeptide
ATE496129T1 (de)	2011-02-15	Von hla-klasse-ii-molekülen präsentierte ssx-2- peptide
DE69942637D1 (de)	2010-09-09	Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
WO2002072763A3 (en)	2003-02-27	Nucleic acids, proteins, and antibodies
WO2001055305A8 (en)	2001-09-07	Nucleic acids, proteins, and antibodies